Methyl selenocysteine: Single-dose pharmacokinetics in men

James R. Marshall, Clement Ip, Karen Romano, Gerald Fetterly, Marwan Fakih, Borko Jovanovic, Marjorie Perloff, James Crowell, Warren Davis, Renee French-Christy, Alexander Dew, Margerie Coomes, Raymond Bergan

Research output: Contribution to journalArticle

22 Citations (Scopus)

Abstract

The recently published report of the SELECT evaluation of selenium and vitamin E provided strong evidence that selenium 200 μg per day in the form of selenomethionine does not protect selenium-replete men against prostate or any other cancer. This seems to refute the result of the much smaller Nutritional Prevention of Cancer (NPC) trial of selenium. Because SELECT did not test the NPC agent, it is possible that the difference between the two trials stems partly from the use of different agents: selenomethionine in SELECT, and selenized yeast in the NPC trial. One of the organic selenium forms suspected of having strong chemopreventive effects, and which may have been present in the NPC agent, is methyl selenocysteine. This study characterizes the single-dose pharmacokinetics of methyl selenocysteine.

Original languageEnglish (US)
Pages (from-to)1938-1944
Number of pages7
JournalCancer Prevention Research
Volume4
Issue number11
DOIs
StatePublished - Nov 2011
Externally publishedYes

Fingerprint

Selenium
Pharmacokinetics
Selenomethionine
Neoplasms
Dried Yeast
Vitamin E
Prostate
selenomethylselenocysteine

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Marshall, J. R., Ip, C., Romano, K., Fetterly, G., Fakih, M., Jovanovic, B., ... Bergan, R. (2011). Methyl selenocysteine: Single-dose pharmacokinetics in men. Cancer Prevention Research, 4(11), 1938-1944. https://doi.org/10.1158/1940-6207.CAPR-10-0259

Methyl selenocysteine : Single-dose pharmacokinetics in men. / Marshall, James R.; Ip, Clement; Romano, Karen; Fetterly, Gerald; Fakih, Marwan; Jovanovic, Borko; Perloff, Marjorie; Crowell, James; Davis, Warren; French-Christy, Renee; Dew, Alexander; Coomes, Margerie; Bergan, Raymond.

In: Cancer Prevention Research, Vol. 4, No. 11, 11.2011, p. 1938-1944.

Research output: Contribution to journalArticle

Marshall, JR, Ip, C, Romano, K, Fetterly, G, Fakih, M, Jovanovic, B, Perloff, M, Crowell, J, Davis, W, French-Christy, R, Dew, A, Coomes, M & Bergan, R 2011, 'Methyl selenocysteine: Single-dose pharmacokinetics in men', Cancer Prevention Research, vol. 4, no. 11, pp. 1938-1944. https://doi.org/10.1158/1940-6207.CAPR-10-0259
Marshall JR, Ip C, Romano K, Fetterly G, Fakih M, Jovanovic B et al. Methyl selenocysteine: Single-dose pharmacokinetics in men. Cancer Prevention Research. 2011 Nov;4(11):1938-1944. https://doi.org/10.1158/1940-6207.CAPR-10-0259
Marshall, James R. ; Ip, Clement ; Romano, Karen ; Fetterly, Gerald ; Fakih, Marwan ; Jovanovic, Borko ; Perloff, Marjorie ; Crowell, James ; Davis, Warren ; French-Christy, Renee ; Dew, Alexander ; Coomes, Margerie ; Bergan, Raymond. / Methyl selenocysteine : Single-dose pharmacokinetics in men. In: Cancer Prevention Research. 2011 ; Vol. 4, No. 11. pp. 1938-1944.
@article{0291925acdd04b888b3bc40643a9018e,
title = "Methyl selenocysteine: Single-dose pharmacokinetics in men",
abstract = "The recently published report of the SELECT evaluation of selenium and vitamin E provided strong evidence that selenium 200 μg per day in the form of selenomethionine does not protect selenium-replete men against prostate or any other cancer. This seems to refute the result of the much smaller Nutritional Prevention of Cancer (NPC) trial of selenium. Because SELECT did not test the NPC agent, it is possible that the difference between the two trials stems partly from the use of different agents: selenomethionine in SELECT, and selenized yeast in the NPC trial. One of the organic selenium forms suspected of having strong chemopreventive effects, and which may have been present in the NPC agent, is methyl selenocysteine. This study characterizes the single-dose pharmacokinetics of methyl selenocysteine.",
author = "Marshall, {James R.} and Clement Ip and Karen Romano and Gerald Fetterly and Marwan Fakih and Borko Jovanovic and Marjorie Perloff and James Crowell and Warren Davis and Renee French-Christy and Alexander Dew and Margerie Coomes and Raymond Bergan",
year = "2011",
month = "11",
doi = "10.1158/1940-6207.CAPR-10-0259",
language = "English (US)",
volume = "4",
pages = "1938--1944",
journal = "Cancer Prevention Research",
issn = "1940-6207",
publisher = "American Association for Cancer Research Inc.",
number = "11",

}

TY - JOUR

T1 - Methyl selenocysteine

T2 - Single-dose pharmacokinetics in men

AU - Marshall, James R.

AU - Ip, Clement

AU - Romano, Karen

AU - Fetterly, Gerald

AU - Fakih, Marwan

AU - Jovanovic, Borko

AU - Perloff, Marjorie

AU - Crowell, James

AU - Davis, Warren

AU - French-Christy, Renee

AU - Dew, Alexander

AU - Coomes, Margerie

AU - Bergan, Raymond

PY - 2011/11

Y1 - 2011/11

N2 - The recently published report of the SELECT evaluation of selenium and vitamin E provided strong evidence that selenium 200 μg per day in the form of selenomethionine does not protect selenium-replete men against prostate or any other cancer. This seems to refute the result of the much smaller Nutritional Prevention of Cancer (NPC) trial of selenium. Because SELECT did not test the NPC agent, it is possible that the difference between the two trials stems partly from the use of different agents: selenomethionine in SELECT, and selenized yeast in the NPC trial. One of the organic selenium forms suspected of having strong chemopreventive effects, and which may have been present in the NPC agent, is methyl selenocysteine. This study characterizes the single-dose pharmacokinetics of methyl selenocysteine.

AB - The recently published report of the SELECT evaluation of selenium and vitamin E provided strong evidence that selenium 200 μg per day in the form of selenomethionine does not protect selenium-replete men against prostate or any other cancer. This seems to refute the result of the much smaller Nutritional Prevention of Cancer (NPC) trial of selenium. Because SELECT did not test the NPC agent, it is possible that the difference between the two trials stems partly from the use of different agents: selenomethionine in SELECT, and selenized yeast in the NPC trial. One of the organic selenium forms suspected of having strong chemopreventive effects, and which may have been present in the NPC agent, is methyl selenocysteine. This study characterizes the single-dose pharmacokinetics of methyl selenocysteine.

UR - http://www.scopus.com/inward/record.url?scp=81555202942&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=81555202942&partnerID=8YFLogxK

U2 - 10.1158/1940-6207.CAPR-10-0259

DO - 10.1158/1940-6207.CAPR-10-0259

M3 - Article

C2 - 21846796

AN - SCOPUS:81555202942

VL - 4

SP - 1938

EP - 1944

JO - Cancer Prevention Research

JF - Cancer Prevention Research

SN - 1940-6207

IS - 11

ER -